Atocha Romero, PharmD, PhD, explains the value of liquid biopsy-based comprehensive genomic profiling. Dr. Romero provides an overview of the results of the NADIM II clinical trials and discusses ctDNA testing to monitor disease and guide treatment. Atocha Romero, PharmD, PhD, is the director of the Liquid Biopsy Laboratory of the Medical Oncology Department at the Hospital Universitario Puerta de Hierro in Madrid, Spain. Learn about liquid biopsy CGP in colorectal cancer: youtu.be/nO-HsxY1afo Learn about minimal residual disease (MRD) and the DYNAMIC trial: youtu.be/slbDjFXkJuk Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illumina